Brief summary

This study is a single-center, open-label, single-arm, dose-escalating investigator-initiated clinical trial (IIT) to evaluate the safety, tolerability and preliminary efficacy of CRTE7A2-01 TCR-T cell injection in patients with HPV16-positive advanced ce

Inclusion Criteria

• Enrollment Requirement: 18~65 years old;

• With inoperable advanced cervical, cancer, head and neck cancer (HPV16 positive and HLA-A*02:01), histologically confirmed as standard therapy failure or intolerance;

• ECOG score is 0~1 points;

• Participants with childbearing potential must agree to adopt highly effective methods of contraception throughout the study period and for at least 6 months after receiving the last treatment, and female of childbearing age must have a negative pregnancy test within 7 days before the treatment;

• Voluntary signing of informed consent letter, and the compliance meet the expectation.

Research Center

• Organizer Hospital

  The First Affiliated Hospital of Zhengzhou University

• Principal Investigator

  Director Zhang Yi